Vaccines for pandemic influenza

A technology of epidemic, influenza virus, applied in the field of vaccine for pandemic influenza

Inactive Publication Date: 2013-02-27
免疫设计公司
View PDF37 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the vaccine must be safe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines for pandemic influenza
  • Vaccines for pandemic influenza
  • Vaccines for pandemic influenza

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0023] A. Preparation of hemagglutinin

[0024] 1. The source of HA

[0025] At least 4 different influenza A viruses are currently of pre-pandemic or pandemic concern: H5N1, H1N1, H7N7, and H9N2.

[0026] Influenza A virus subtype H5N1 is a subtype of influenza A virus that can cause disease in humans and many other animal species. A highly pathogenic strain of H5N1 (HPAI H5N1) is the cause of "bird flu" or "bird flu". It is currently a disease of poultry and although it can infect humans, most or all of it has had extensive physical contact with infected birds. H5N1 is classified as a pre-pandemic virus because not all the conditions for a pandemic have been met, most notably the inability of the virus to spread easily and sustainably between humans.

[0027] Avian influenza of the H5N1 type (referred to herein as "H5N1") first emerged in Asia and has spread globally. H5N1 viruses continue to evolve and can now be classified into different clades and subclades based on t...

Embodiment 1

[0124] Efficacy of a single injection of rH5 / GLA-SE influenza vaccine in mice

[0125] This example shows that a single vaccination with recombinant influenza virus H5 (rH5) protein is effective in eliciting a protective antiviral immune response in mice challenged with high titer H5N1 virus. rH5 protein (derived from H5N1 Viet Nam 1203; available from Protein Sciences, Meriden, CT) alone or formulated with GLA-SE adjuvant in increasing amounts (0, 50, 150, 450, 900 or 2700 ng) Balb / c mice (5 / group) were injected intramuscularly (IM) once with (20 μg of GLA in 2% SE). Pass H5N1Viet Nam 1203 after 14 days (1000xLD 50 ) to challenge mice with intranasal administration. Mice were monitored daily for weight loss and euthanized if the weight loss exceeded 20-30%. Vaccination with rH5 protein alone did not provide protective immunity, as all mice injected with rH5 in the absence of adjuvant died spontaneously after virus challenge (18 / 25 animals) or showed overt morbidity and Eu...

Embodiment 2

[0131] rH5 / GLA-SE influenza vaccine confers heterologous immunity in mice when administered as a single injection

[0132] In this example, the protective efficacy of recombinant vaccines formulated with GLA adjuvant against heterologous virus challenge is demonstrated. For these experiments, mice were immunized with a single injection of rH5 protein isolated from H5N1 Indonesia (clade 2.3), and then challenged with H5N1 VN virus, as described above. As a positive control, mice were inoculated with the homologous rH5 protein from H5N1 Vietnam, while as a negative control, mice were inoculated with an irrelevant HSV-2 viral protein (rG013). As shown in Table 1, all mice vaccinated with HSV-2 died regardless of the protein-adjuvant formulation. All mice vaccinated with 50 ng of homologous rH5VN protein alone died, whereas all mice vaccinated with rH5VN formulated with GLA-SE adjuvant survived, consistent with previous findings. Importantly, all mice receiving 50ng or 200ng of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.

Description

[0001] Statement Regarding Federally Funded Research [0002] This invention was made with government support under 5R43AI081383-02 awarded by the National Institute of Allergy and Infectious Diseases. The government may have certain rights in this invention. technical field [0003] This patent application generally relates to compositions for use as vaccines for pre-pandemic or pandemic influenza, such as avian influenza (eg, H5N1), swine influenza (eg, H1N1), H7N7, and H9N2. Compositions generally comprise recombinant hemagglutinin from a candidate influenza virus and an adjuvant. Background technique [0004] A pandemic is a global pandemic of an infectious disease that persists when a new disease emerges, infects people (thereby causing severe disease) and spreads rapidly among people. An influenza pandemic can occur when a new strain or subtype of an influenza virus spreads from another animal species, such as birds or pigs, into a population lacking immunity from pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/145A61K39/39
CPCA61K2039/55583A61K2039/55511A61K39/12C12N2760/16234C12N2760/16134A61P31/16A61P37/04A61K9/0019A61K39/145
Inventor 克里斯多福·H·克雷格史提芬·G·里德尼尔·凡·霍芬
Owner 免疫设计公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap